Additional Administration Option Approved for Nuplazid Capsules
Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Neurology
Investigational Drug May Prolong Survival in Patients With ALS
Median survival 6.5 months longer with initiation of PB-TURSO treatment compared with placebo.
Elezanumab Granted Orphan Drug, Fast Track Designations for Spinal Cord Injury
Elezanumab is a monoclonal antibody of the human IgG1 isotype that works by binding selectively to repulsive guidance molecule A.
Cognition-Enhancing Supplements May Contain Unapproved Drugs
Five unapproved pharmaceutical drugs ID’d in supplements marketed to improve memory, cognition
FDA: Stimulation Trial Should Be Performed Before Implanting SCS for Pain
The FDA reported that between July 27, 2016 and July 27, 2020, a total of 107,728 medical device reports (MDRs) associated with SCS devices intended for pain were received.
Sodium Phenylbutyrate-Taurursodiol Promising for ALS
Slower functional decline seen with active drug versus placebo through 24 weeks
Pimavanserin sNDA Under Review for Dementia-Related Psychosis
The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Pimavanserin sNDA Submitted for Dementia-Related Psychosis
Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Investigational Treatment for PML Gets Orphan Drug Status
The FDA has granted Orphan Drug designation to NT-I7 (efineptakin alfa; NeoImmuneTech) for the treatment of progressive multifocal leukoencephalopathy.
Higher Doses of Deutetrabenazine Examined in Patients With Huntington Disease-Associated Chorea
Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea, according to a recently published post-hoc analysis.
